{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:02:35Z","timestamp":1791928955897,"version":"4.3.4"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T00:00:00Z","timestamp":1677456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016814","name":"Marinus Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016814","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.eplepsyres.2023.107112","type":"journal-article","created":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T07:19:50Z","timestamp":1677050390000},"page":"107112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Phase 2, placebo-controlled clinical study of oral ganaxolone in PCDH19-clustering epilepsy"],"prefix":"10.1016","volume":"191","author":[{"given":"Joseph","family":"Sullivan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boudewijn","family":"Gunning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Zafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renzo","family":"Guerrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jozef","family":"Gecz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristy L.","family":"Kolc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Gasior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex A.","family":"Aimetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debopam","family":"Samanta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.eplepsyres.2023.107112_bib1","first-page":"283","article-title":"The Aberrant Behavior Checklist-Community: factor validity and effect of subject variables for adults in group homes","volume":"100","author":"Aman","year":"1995","journal-title":"Am. J. Ment. Retard."},{"issue":"7","key":"10.1016\/j.eplepsyres.2023.107112_bib2","first-page":"28","article-title":"The clinical global impressions scale: applying a research tool in clinical practice","volume":"4","author":"Busner","year":"2007","journal-title":"Psychiatry"},{"issue":"1","key":"10.1016\/j.eplepsyres.2023.107112_bib3","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.yebeh.2012.02.023","article-title":"Cognitive and behavioral profile in females with epilepsy with PDCH19 mutation: two novel mutations and review of the literature","volume":"24","author":"Camacho","year":"2012","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2023.107112_bib4","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.yebeh.2014.10.019","article-title":"Cognitive development in females with PCDH19 gene-related epilepsy","volume":"42","author":"Cappelletti","year":"2015","journal-title":"Epilepsy Behav."},{"issue":"3","key":"10.1016\/j.eplepsyres.2023.107112_bib5","first-page":"1284","article-title":"Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one), a selective, high-affinity, steroid modulator of the gamma-aminobutyric acid(A) receptor","volume":"280","author":"Carter","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.eplepsyres.2023.107112_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1000381","article-title":"Sporadic infantile epileptic encephalopathy caused by mutations in PCDH19 resembles Dravet syndrome but mainly affects females","volume":"5","author":"Depienne","year":"2009","journal-title":"PLoS Genet."},{"issue":"1","key":"10.1016\/j.eplepsyres.2023.107112_bib7","doi-asserted-by":"crossref","first-page":"E1959","DOI":"10.1002\/humu.21373","article-title":"Mutations and deletions in PCDH19 account for various familial or isolated epilepsies in females","volume":"32","author":"Depienne","year":"2011","journal-title":"Hum. Mutat."},{"issue":"6","key":"10.1016\/j.eplepsyres.2023.107112_bib8","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/ng.149","article-title":"X-linked protocadherin 19 mutations cause female-limited epilepsy and cognitive impairment","volume":"40","author":"Dibbens","year":"2008","journal-title":"Nat. Genet."},{"issue":"1\u20132","key":"10.1016\/j.eplepsyres.2023.107112_bib9","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.eplepsyres.2013.04.005","article-title":"PCDH19-related female-limited epilepsy: further details regarding early clinical features and therapeutic efficacy","volume":"106","author":"Higurashi","year":"2013","journal-title":"Epilepsy Res."},{"issue":"5","key":"10.1016\/j.eplepsyres.2023.107112_bib10","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1474-4422(22)00077-1","article-title":"Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial","volume":"21","author":"Knight","year":"2022","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.eplepsyres.2023.107112_bib11","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41380-018-0066-9","article-title":"A systematic review and meta-analysis of 271 PCDH19-variant individuals identifies psychiatric comorbidities, and association of seizure onset and disease severity","volume":"24","author":"Kolc","year":"2019","journal-title":"Mol. Psychiatry"},{"issue":"1","key":"10.1016\/j.eplepsyres.2023.107112_bib12","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41398-020-0803-0","article-title":"A standardized patient-centered characterization of the phenotypic spectrum of PCDH19 girls clustering epilepsy","volume":"10","author":"Kolc","year":"2020","journal-title":"Transl. Psychiatry"},{"issue":"11","key":"10.1016\/j.eplepsyres.2023.107112_bib13","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1080\/14737175.2021.1904895","article-title":"Ganaxolone treatment for epilepsy patients: from pharmacology to place in therapy","volume":"21","author":"Lattanzi","year":"2021","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.eplepsyres.2023.107112_bib14","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.seizure.2016.01.006","article-title":"Effectiveness of antiepileptic therapy in patients with PCDH19 mutations","volume":"35","author":"Lotte","year":"2016","journal-title":"Seizure"},{"issue":"7","key":"10.1016\/j.eplepsyres.2023.107112_bib15","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1080\/09297049.2017.1365829","article-title":"Utility of the behavior rating inventory of executive function - preschool version (BRIEF-P) in young children with epilepsy","volume":"24","author":"Maiman","year":"2018","journal-title":"Child Neuropsychol."},{"key":"10.1016\/j.eplepsyres.2023.107112_bib16","series-title":"ZTALMY [Prescribing Information]","author":"Marinus Pharmaceuticals, Inc","year":"2022"},{"issue":"7","key":"10.1016\/j.eplepsyres.2023.107112_bib17","article-title":"Adjuvant treatment for protocadherin 19 (PCDH19) syndrome","volume":"14","author":"Moncayo","year":"2022","journal-title":"Cureus"},{"issue":"8","key":"10.1016\/j.eplepsyres.2023.107112_bib18","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1093\/sleep\/23.8.1d","article-title":"The Children's Sleep Habits Questionnaire (CSHQ): psychometric properties of a survey instrument for school-aged children","volume":"23","author":"Owens","year":"2000","journal-title":"Sleep"},{"key":"10.1016\/j.eplepsyres.2023.107112_bib19","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejpn.2019.12.020","article-title":"Levetiracetam efficacy in PCDH19 girls clustering epilepsy","volume":"24","author":"Sadleir","year":"2020","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.eplepsyres.2023.107112_bib20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.pediatrneurol.2019.10.009","article-title":"PCDH19-related epilepsy syndrome: a comprehensive clinical review","volume":"105","author":"Samanta","year":"2020","journal-title":"Pediatr. Neurol."},{"issue":"Pt. 4","key":"10.1016\/j.eplepsyres.2023.107112_bib21","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1093\/brain\/awm338","article-title":"Epilepsy and mental retardation limited to females: an under-recognized disorder","volume":"131","author":"Scheffer","year":"2008","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.eplepsyres.2023.107112_bib22","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/epi.14003","article-title":"PCDH19-related epilepsy is associated with a broad neurodevelopmental spectrum","volume":"59","author":"Smith","year":"2018","journal-title":"Epilepsia"},{"issue":"7","key":"10.1016\/j.eplepsyres.2023.107112_bib23","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1111\/j.1528-1167.2011.03063.x","article-title":"Spectrum of phenotypes in female patients with epilepsy due to protocadherin 19 mutations","volume":"52","author":"Specchio","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2023.107112_bib24","unstructured":"Sullivan, J., Specchio, N., Chez, M.G., Pinna, G., Loc, A., 2018. Preliminary evidence of a predictive clinical biomarker in PCDH19-related epilepsy: significant treatment effect of ganaxolone in biomarker-positive patients [abstract]. Presented at American Epilepsy Society Annual Meeting, December 2\u20133, 2018, New Orleans, LA."},{"issue":"18","key":"10.1016\/j.eplepsyres.2023.107112_bib25","doi-asserted-by":"crossref","first-page":"5250","DOI":"10.1093\/hmg\/ddv245","article-title":"Mutations of protocadherin 19 in female epilepsy (PCDH19-FE) lead to allopregnanolone deficiency","volume":"24","author":"Tan","year":"2015","journal-title":"Hum. Mol. Genet."},{"issue":"6","key":"10.1016\/j.eplepsyres.2023.107112_bib26","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1111\/epi.13772","article-title":"Reduced steroidogenesis in patients with PCDH19-female limited epilepsy","volume":"58","author":"Trivisano","year":"2017","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.eplepsyres.2023.107112_bib27","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10048-013-0353-1","article-title":"Clinical and genetic aspects of PCDH19-related epilepsy syndromes and the possible role of PCDH19 mutations in males with autism spectrum disorders","volume":"14","author":"van Harssel","year":"2013","journal-title":"Neurogenetics"}],"updated-by":[{"DOI":"10.1016\/j.eplepsyres.2024.107342","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000}}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121123000372?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121123000372?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T11:23:49Z","timestamp":1708082629000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121123000372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":27,"alternative-id":["S0920121123000372"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2023.107112","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.eplepsyres.2024.107342","asserted-by":"object"}]},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 2, placebo-controlled clinical study of oral ganaxolone in PCDH19-clustering epilepsy","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2023.107112","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107112"}}